Overvåkning av pankreas helse etter diabetesdiagnose (SAFE-D)
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
- attend 3 study visits over 12 months time
- provide a blood sample at each study visit
- complete an anxiety questionnaire at each visit.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.
There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.
People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.
The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.
Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: SAFE-D Trial Manager
- Telefonnummer: +442381205154
- E-post: safed@soton.ac.uk
Studiesteder
-
-
-
Ashton-under-Lyne, Storbritannia, OL6 6HD
- Aktiv, ikke rekrutterende
- Ashton Medical Group
-
Birmingham, Storbritannia, B14 4DU
- Rekruttering
- Yardley Wood Health Centre
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Bournemouth, Storbritannia, BH7 7DW
- Aktiv, ikke rekrutterende
- Bournemouth Research Hub
-
Bromborough, Storbritannia, CH62 6EE
- Rekruttering
- Eastham Group Practice
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
London, Storbritannia, NW10 2PT
- Rekruttering
- Willesden Medical Centre
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
London, Storbritannia, SW1P 2PF
- Rekruttering
- South Westminster Centre
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
London, Storbritannia, W7 1DR
- Rekruttering
- The Cuckoo Lane Practice
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Manchester, Storbritannia, M14 6WP
- Aktiv, ikke rekrutterende
- Bodey Medical Centre
-
Manchester, Storbritannia, M23 1JX
- Aktiv, ikke rekrutterende
- Bowland Medical Practice
-
Manchester, Storbritannia, M23 2SY
- Aktiv, ikke rekrutterende
- The Maples Medical Centre
-
Nottingham, Storbritannia, NG17 4JL
- Rekruttering
- King's Mill Hospital (Sherwood Forest) Research Van
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Portsmouth, Storbritannia, PO1 3HN
- Aktiv, ikke rekrutterende
- Portsmouth Research Hub
-
Rossendale, Storbritannia, BB4 5SL
- Rekruttering
- Hazelvalley Family Practice
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Ruislip, Storbritannia, HA4 8NX
- Rekruttering
- Pembroke Centre (Hillingdon)
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Southampton, Storbritannia, SO30 3JB
- Rekruttering
- Moorgreen Hospital
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Southampton, Storbritannia, SO15 33UA
- Aktiv, ikke rekrutterende
- Southampton Research Hub (Shirley Research Hub)
-
Uttoxeter, Storbritannia, ST14 8JG
- Rekruttering
- Balance Street Health Centre
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Uxbridge, Storbritannia, UB8 1UW
- Rekruttering
- Civic Centre
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Walsall, Storbritannia, WS6 6EW
- Rekruttering
- Quinton Practice
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Weymouth, Storbritannia, DT4 0QE
- Aktiv, ikke rekrutterende
- Weymouth Research Hub
-
-
Cheshire
-
Sandbach, Cheshire, Storbritannia, CW11 1EQ
- Aktiv, ikke rekrutterende
- Ashfields Primary Care Centre
-
-
Kent
-
Maidstone, Kent, Storbritannia, ME16 9QQ
- Rekruttering
- Maidstone and Tunbridge Wells NHS Trust
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
-
Leicester Forest East
-
Leicester, Leicester Forest East, Storbritannia, LE3 3LW
- Rekruttering
- Forest Medical Group
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
-
Leicestershire
-
Kibworth Beauchamp, Leicestershire, Storbritannia, LE8 0LG
- Rekruttering
- South Leicestershire Medical Group
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
-
Staffordshire
-
Burton-on-Trent, Staffordshire, Storbritannia, DE14 3RH
- Rekruttering
- Peel Croft Surgery
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Kingswinford, Staffordshire, Storbritannia, DY6 8DN
- Rekruttering
- Kingswinford Medical Practice
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Leek, Staffordshire, Storbritannia, ST13 6QR
- Rekruttering
- Park Medical Centre
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Stratford-upon-Avon, Staffordshire, Storbritannia, CV37 6HJ
- Rekruttering
- Trinity Court Surgery
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
-
Surrey
-
Brockham, Surrey, Storbritannia, RH3 7NJ
- Rekruttering
- Brockwood Medical Practice
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Epsom, Surrey, Storbritannia, KT17 4BL
- Rekruttering
- Integrated Care Partnership/ The Old Cottage Hospital
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
Warlingham, Surrey, Storbritannia, CR6 9NW
- Rekruttering
- Warlingham Green Medical Practice
-
Ta kontakt med:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-post: safed@soton.ac.uk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI or CT scan
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria:
- Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for or confirmed pancreatic cancer
- Under investigation/surveillance for pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- BMI > 40 at the time of consent
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Interventional
Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team. |
Avantect test |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sensitivity of the Avantect test
Tidsramme: The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed. |
The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
|
Specificity of the Avantect test
Tidsramme: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Stage shift
Tidsramme: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data. Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
Tidsramme: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
Tidsramme: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resection rate of pancreatic cancer
Tidsramme: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resectability
Tidsramme: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of pancreatic cancers deemed resectable by the study MDST. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time-to-event outcomes
Tidsramme: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Overall survival
Tidsramme: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the overall survival of study participants. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Effect of the Avantect test on state anxiety over time
Tidsramme: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To assess the effect of the Avantect test on state anxiety over time. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
High-grade neoplasia
Tidsramme: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To investigate the performance characteristics for high-grade neoplasia. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Neoplasmer etter nettsted
- Neoplasmer
- Metabolske sykdommer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Glukosemetabolismeforstyrrelser
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Ernæringsmessige og metabolske sykdommer
- Diabetes mellitus, type 2
- Neoplasmer i bukspyttkjertelen
- Sukkersyke
- Kreft i bukspyttkjertelen, voksen
Andre studie-ID-numre
Andre studie-ID-numre
- RHMGSU0292
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .